Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LENZthis companyLENZ Therapeutics, Inc.	$3.94	-5.61×	1.62×	24.15×	-5.37×	-23.7%	96.3%	-477.5%	-430.3%	-28.9%	-32.0%	-15.2%	0×	0.3×	0×	14.23×	0.0%	1	0.7	1	C-
ABUSArbutus Biopharma Corp	$3.67	-28.29×	12.04×	65.44×	-27.47×	-163.1%	97.4%	-192.1%	-237.9%	-43.7%	-30.3%	-4.3%	0.05×	0.42×	-278.88×	15.73×	0.0%	5	28.57	4	A-
GERNGeron Corporation	$0.99	-10.15×	3.9×	4.79×	-20.26×	-808.4%	97.4%	-29.3%	-46.7%	-38.0%	-11.3%	-12.6%	1.11×	-3.32×	-1.65×	4.66×	0.0%	1	-2.78	1	C-
MRVIMaravai LifeSciences Holdings, Inc.	$8.00	-3.57×	2.22×	2.54×	-4.86×	-66.3%	18.0%	-3.6%	-70.4%	-61.6%	-0.9%	-15.0%	0.17×	1.23×	-0.25×	6.6×	0.0%	4	4.88	1	C-
PRMEPrime Medicine, Inc.	$4.37	-2.57×	4.27×	111.44×	-2.91×	-102.2%	-58.1%	-4498.1%	-4342.4%	-166.4%	-66.5%	-32.4%	0.96×	-0.27×	0×	4.84×	0.0%	2	-5.36	1	D+
RZLTRezolute, Inc.	$4.12	-6.93×	5.37×	0×	-6.4×	-98.6%	0.0%	0.0%	0.0%	-77.1%	-81.3%	-12.0%	0.01×	0.12×	0×	9.44×	0.0%	1	11.27	2	C
Peer median	—	-6.93×	4.27×	4.79×	-6.4×	-102.2%	18.0%	-29.3%	-70.4%	-61.6%	-30.3%	-12.6%	0.17×	0.12×	-0.25×	6.6×	0.0%	2	4.88	1	—